%0 Journal Article
%T Hyperhomocysteinemia and Type 2 Diabetes in C£¿te d'Ivoire SciDoc Publishers | Open Access | Science Journals | Media Partners
%A Acka F
%A Ake M
%A Kouassi D
%A N¡¯Guessan-Blao R
%A Ocho-Anin Atchibri AL
%A Zanon TG
%A Diagou JJ
%J Food Science, Nutrition and Dietetics (IJFS)
%D 2018
%R http://dx.doi.org/10.19070/2326-3350-1800069
%X Abstract The hyperhomocysteinemia is associated with the development and the accentuation of the cardiovascular complications of the type 2 diabetes. The objective of this study was to evaluate the hyperhomocysteinemia in type 2 diabetic patients. This study was carried out in 200 volunteer type 2 diabetics, regularly monitored at the Antidiabetic Center of Abidjan (CADA). The non-diabetic control population was composed of 31 healthy presumptive volunteers. The homocysteine, the glycemia and the lipid parameters were measured by enzymatic methods on the biochemistry automaton Cobas c-311(Roche Diagnostics). The present study has revealed a prevalence of a moderate hyperhomocysteinemia of 36.50%. The average hyperhomocysteinemia was of 14.84 ¡À 3.26 ¦Ìmol/L. It was higher in men (14.95 ¡À 3.50¦Ìmol/L) than in women (14.75 ¡À 3.05¦Ìmol/L), with no significant difference, and was predominant in the Akan ethnic group (57.53%). It evolved with age and was significantly increased between 50 and 70 years. The relative risk of the hyperhomocysteinemia was approximately 3 (RR = 2.83¡Ö3, CI 95%: 1.39-11.53, P(¦Ö2) <0.05). That suggests an association between the hyperhomocysteinemia and the type 2 diabetes. The observed ¦Ö2 is greater than ¦Ö2 (1; 0.95), giving to think that the hyperhomocysteinemia risk is significantly higher in diabetic hyperhomocyteinemic patients than in non-diabetic controls. Moreover, there was a significant difference of homocysteinemia between that of the hyperhomocysteinemic diabetics (14.84 ¡À 3.26 ¦Ìmol/L) and the control group (10.74 ¡À 2.38 ¦Ìmol/L). That suggests an increased involvement of the hyperhomocysteinemia in the development of the cardiovascular diseases in our diabetic patients. However, the lipid parameters are normalized in our hyperhomocysteinemic diabetic patients, due to the effect of the clinical and nutritional treatment. The hyperhomocysteinemia is a reality in C£¿te d'Ivoire. It should be the object of sensibilization and reinforcement of the dietary and therapeutic measures, in order to minimize the risk of the cardiovascular diseases incurred by the type 2 diabetics
%K Hyperhomocysteinemia
%K Cardiovascular Risk Factor
%K Type 2 Diabetes.
%U https://scidoc.org/IJFS-2326-3350-07-401.php